☆ 4.7 Article

Distinct immune responses in the early phase to natural SARS-CoV-2 infection or vaccination

JOURNAL OF MEDICAL VIROLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Public, Environmental & Occupational Health

Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers

H. Demirbakan et al.

Summary: This study aimed to assess the humoral immunity in healthcare workers (HCWs) vaccinated with an inactive virus vaccine (CoronaVac) and found that CoronaVac was highly immunogenic in HCWs, but the immunogenicity declined significantly after 3 months following the second dose of vaccine.

PUBLIC HEALTH (2022)

Add to Collection

Article Infectious Diseases

Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa

F. Abdullah et al.

Summary: This study analyzed the clinical data of COVID-19 patients admitted to a hospital in Tshwane during the Omicron wave, and found that the severity of the disease was decreased compared to previous waves, with lower death rates and ICU admissions.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

Add to Collection

Article Multidisciplinary Sciences

Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein

Emi E. Nakayama et al.

Summary: A cytokine storm is the main cause of death in COVID-19 patients, and the production of IL-6 in SARS-CoV-2-infected alveoli is influenced by the N protein-coding plasmid and anti-N antibody.

SCIENTIFIC REPORTS (2022)

Add to Collection

Article Immunology

A Third Dose of an Inactivated Vaccine Dramatically Increased the Levels and Decay Times of Anti-SARS-CoV-2 Antibodies, but Disappointingly Declined Again: A Prospective, Longitudinal, Cohort Study at 18 Serial Time Points Over 368 Days

Xian-Ming Liang et al.

Summary: This study investigated the responses and durations of five subsets of anti-SARS-CoV-2 antibodies after three doses of inactivated SARS-CoV-2 vaccines. The results showed that the third dose significantly increased antibody levels and duration, but the half-life of neutralizing antibody remained unsatisfactory.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Immunology

The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections

Ren-Jun Hsu et al.

Summary: This review focuses on the cytokine storm in COVID-19, discussing its pathological features and potential immunotherapeutic approaches. Using cytokines as diagnostic markers and proactively managing the cytokine storm can improve disease outcomes and prognosis.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Immunogenic SARS-CoV-2 S and N Protein Peptide and Cytokine Combinations as Biomarkers for Early Prediction of Fatal COVID-19

Ekaterina Martynova et al.

Summary: This study analyzed and quantified the reactivity of serum samples from COVID-19 patients to identify markers for predicting fatality risks. Differences in immune response and cytokine activation were observed between fatal and non-fatal patients. Specific peptides with longer immune response were identified. A panel of biomarkers for early prediction of COVID-19 fatality risk was proposed based on the analysis of IgM antibody reactivity and cytokine profiles.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Letter Infectious Diseases

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

Wey Wen Lim et al.

LANCET MICROBE (2021)

Add to Collection

Review Virology

Immune response following infection withSARS-CoV-2 and other coronaviruses: A rapid review

Eamon O. Murchu et al.

Summary: Evidence on the immune response and reinfection rate following SARS-CoV-2 infection was systematically searched and summarized. Most patients seroconverted for SARS-CoV-2-specific IgG within 2 weeks. Studies on SARS-CoV suggest sustained SARS-CoV-specific IgG for 1-2 years post-infection.

REVIEWS IN MEDICAL VIROLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

Rajendra Karki et al.

Summary: The combination of TNF-alpha and IFN-gamma induces inflammatory cell death characterized by PANoptosis, which can be inhibited to protect mice from the pathological effects and death caused by COVID-19. Blocking the cytokine-mediated inflammatory cell death signaling pathway may benefit patients with COVID-19 or other infectious and autoinflammatory diseases by limiting tissue damage/inflammation.

CELL (2021)

Add to Collection

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

News Item Multidisciplinary Sciences

HEAVILY MUTATED OMICRON VARIANT PUTS SCIENTISTS ON ALERT

Ewen Callaway

NATURE (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccines

C. Buddy Creech et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Detection of a SARS-CoV-2 variant of concern in South Africa

Houriiyah Tegally et al.

Summary: The article describes a newly emerged lineage of SARS-CoV-2, 501Y.V2, characterized by eight mutations in the spike protein, which may result in increased transmissibility or immune escape. This lineage originated in South Africa and quickly became dominant in Eastern Cape, Western Cape, and KwaZuluNatal provinces within weeks.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Nicholas G. Davies et al.

Summary: A new variant of SARS-CoV-2 has emerged in England, with a higher reproduction number and potential for large resurgences of COVID-19 cases. Without stringent control measures, it is projected that COVID-19 hospitalizations and deaths in England for the first 6 months of 2021 will exceed those in 2020. The variant has spread globally and exhibited similar transmission increases in Denmark, Switzerland, and the United States.

SCIENCE (2021)

Add to Collection

Review Medicine, General & Internal

SARS-CoV-2 vaccines: Lights and shadows

Fabio Angeli et al.

Summary: SARS-CoV-2 vaccines can elicit immune responses but concerns about cardiovascular adverse reactions have been raised. Vaccines can increase Spike protein synthesis and immune responses, with genetic and immunological factors possibly impacting reactions.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2021)

Add to Collection

Article Immunology

Enhanced Immunogenicity of a Whole-Inactivated Influenza A Virus Vaccine Using Optimised Irradiation Conditions

Eve Victoria Singleton et al.

Summary: In this study, the immunogenicity of gamma-irradiated influenza vaccine under different temperature conditions was compared, and it was found that regardless of temperature, the structural integrity and vaccine efficacy were well maintained. Interestingly, using higher temperature and lower radiation dose seemed to induce stronger immune responses. This suggests that simplifying irradiation protocols to manufacture effective irradiated vaccines may be possible.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines

Renee W. Y. Chan et al.

Summary: Comirnaty vaccine induces mucosal IgA and IgG responses with neutralizing activity, while CoronaVac vaccine primarily induces IgG responses in plasma, demonstrating differences in immune response between the two vaccine platforms.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination

Rafael Assis et al.

Summary: Analysis of two ongoing COVID-19 longitudinal serological surveys in Orange County, CA revealed a significant increase in antibody levels post-vaccination, with mRNA vaccination inducing a stronger and broader antibody response compared to SARS-CoV-2 infection. Nucleocapsid protein antibodies can differentiate vaccinees, and previously infected individuals exhibit higher antibody titers to the vaccine.

NPJ VACCINES (2021)

Add to Collection

Article Cell Biology

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

Yunlong Cao et al.

Summary: The study found that the diversity of anti-RBD NAbs plays a major role in neutralization against SARS-CoV-2 variants, especially 501Y.V2, with E484K being the dominant cause of neutralization reduction. Specific antibodies respond differently to mutations in RBD variants, with lower diversity observed in NTD antibodies. RBD-subunit vaccinees exhibit higher tolerance to neutralization against variants, while extending the interval between doses of ZF2001 enhances neutralizing activity and tolerance to variants.

CELL RESEARCH (2021)

Add to Collection

Article Virology

The Interleukin-33 Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine

Clare M. Williams et al.

Summary: IL-33 can enhance the efficacy of influenza vaccines by activating ILC2s, thereby promoting mucosal humoral immunity and cross-strain protection against influenza. This previously unrecognized role of the IL-33-ILC2 axis may aid in the development of a universal influenza vaccine.

JOURNAL OF VIROLOGY (2021)

Add to Collection

Letter Cell Biology

Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine

Pai Peng et al.

CELL DISCOVERY (2021)

Add to Collection

Article Microbiology

Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects

Sarah E. Wheeler et al.

Summary: Understanding the development and duration of virus-specific antibodies after COVID-19 vaccination is important for controlling the pandemic. Postvaccination antibody testing can help in monitoring individuals after vaccination and selecting those who may require additional doses or not need vaccination.

MICROBIOLOGY SPECTRUM (2021)

Add to Collection

Letter Immunology

The role of IgA in COVID-19

Yin Xia Chao et al.

BRAIN BEHAVIOR AND IMMUNITY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to SARS-CoV-2 in patients with COVID-19

Quan-Xin Long et al.

NATURE MEDICINE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

SARS-CoV-2 infection: The role of cytokines in COVID-19 disease

Victor J. Costela-Ruiz et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

Bette Korber et al.

CELL (2020)

Add to Collection

Review Immunology

Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past

Vibhuti Kumar Shah et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Medical Laboratory Technology

Cytokine storm induced by SARS-CoV-2

Peipei Song et al.

CLINICA CHIMICA ACTA (2020)

Add to Collection

Review Immunology

Cytokine Response in SARS-CoV-2 Infection in the Elderly

Subuhi Sherwani et al.

JOURNAL OF INFLAMMATION RESEARCH (2020)

Add to Collection

Article Immunology

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

Huan Han et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

Article Infectious Diseases

Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination

Kawsar R. Talaat et al.

INFLUENZA AND OTHER RESPIRATORY VIRUSES (2018)

Add to Collection

Review Infectious Diseases

Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?

Shin-ichi Tamura et al.

JAPANESE JOURNAL OF INFECTIOUS DISEASES (2016)

Add to Collection

Article Immunology

DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza

J. Williman et al.

VACCINE (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.